FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044394945> ?p ?o ?g. }

• W2044394945 endingPage "1784" @default.
• W2044394945 startingPage "1783" @default.
• W2044394945 abstract "Serologic identification of circulating autoantibodies has proven useful in the diagnosis of patients with autoimmune disorders. In vitro and in vivo1–5 observations suggest that some autoantibodies are more than just serologic markers; they also participate in the pathogenesis of disease. Shining examples of pathogenic autoantibodies are anti-glomerular basement membrane (anti-GBM) autoantibodies found in anti-GBM disease and the Goodpasture syndrome. In 1967, Lerner and colleagues transferred autoantibodies purified from sera of a patient with anti-GBM disease to recipient monkeys and induced glomerulonephritis.1 Nearly half a century of investigation has served to refine our understanding of these autoantibodies and the havoc they cause. Detection of anti-GBM autoantibodies in patients with glomerulonephritis prompts emergent therapy, and frequently patients on dialysis with persistent anti-GBM antibodies are not eligible for kidney transplantation until their autoantibody titers are reduced to near normal levels. In this issue of JASN, Olson and colleagues6 present an intriguing observation of serologic detection of anti-GBM autoantibodies in ostensibly healthy individuals for months if not years before the onset of their anti-GBM disease. This observation is surprising, yet it should not be so, as circulating autoantibodies have been found in healthy individuals who eventually develop other autoimmune diseases. For example, 88% of SLE patients have autoantibodies to at least one autoantigen while clinically asymptomatic.7 These autoantibodies are detectable in multiple samplings for years before diagnosis. It appears that what tips the balance into the clinical presentation of lupus is accumulation of multiple diverse autoantibodies.7 The question that arises with the finding of Olson and colleagues is what triggers the crucial hit that pushes individuals into anti-GBM disease, when they have had years of health with circulating anti-GBM autoantibodies.6 Explanations to consider include that the reactive sites of these autoantibodies found before the onset of disease are restricted to regions of the α3(IV)NC1 domain of type IV collagen that are nonpathogenic, that is, they do not recognize crucial pathogenic epitopes; that the crucial pathogenic autoantibody is readily available but the target epitope on the autoantigen is hidden; or that these autoantibodies have nothing to do with the pathogenesis of disease. In the case of anti-GBM disease, this last possibility appears remote. The presence of serologically detectable anti-GBM autoantibodies over years before disease onset compels one to consider what predisposed these individuals to develop disease. Were they naturally occurring autoantibodies, which are known to exist in a number of autoimmune diseases including anti-GBM antibody disease8 and ANCA vasculitis?9 Characteristically, these antibodies have low affinity and avidity for their target antigens and thus are less likely to be pathogenic. The benign nature of naturally occurring autoantibodies makes it more likely that the anti-GBM autoantibodies observed by Olsen and colleagues6 represent either pathogenic or nonpathogenic autoantibodies, considering that all of the patients in the study eventually developed clinical disease. If these were nonpathogenic, it is possible these autoantibodies were present in the absence of a clinical phenotype because none reacted with a critical epitope required for disease. The pre-existing autoantibodies were lying-in-wait for that final trigger: a response to a molecular mimic or exposure to a complementary protein structure that triggers production of the crucial pathogenic autoantibodies10,11 or an alteration in the collagen microenvironment.12 Fine mapping of epitope specificity would help clarify whether this is the case, but to date, anti-α3(IV)NC1 autoantibodies identified in healthy humans have not been studied in this detail.8 A second and more probable possibility is that pathogenic autoantibodies are available for months to years before disease but their target epitope is concealed. Pedchenko and colleagues have demonstrated the conformational nature of collagen molecules in the glomerular basement membrane during active anti-GBM disease.13 Somehow, a conformation-dependent disease-related epitope is exposed by disassociation of the endogenous hexamer structure of the α3 chain of type IV collagen.13 The cause of disruption in the hexamer structure is unknown. Do naturally occurring autoantibodies contribute to disruption, or is it due to posttranslational changes, proteolytic cleavage by exogenous environmental factors, or is it a combination of events? Conceivably, asymptomatic autoantibodies reactive to one part of a target antigen could reveal or disrupt autoantigen conformation to expose a cryptic epitope. Recently, a mechanism underpinning display of critical autoantigens was described that brought into play alterations in epigenetic regulation of the ANCA antigen proteinase 3 (PR3) and myeloperoxidase (MPO) genes.14 The loss of epigenetic control of these potential antigens results in transcription, likely leading to production of excessive and perhaps aberrant protein. This begs the question of whether changes in these antigens provide a path for production of naturally occurring antibodies that sets the stage for later onset of disease and moreover, whether this is a direct path for generation of the crucial pathogenic antibodies. To take this one step further, is the relapse and remission phenotype of many autoimmune diseases a consequence of changes in antigen integrity or antigen availability? The relative rarity of the autoimmune disease most assuredly requires more than a one-hit and probably more than a two-hit phenomena to incite disease. Multiple hits must be required, including a susceptible genetic background (especially HLA genes)15 and disregulated T and B cells.16–18 Yet the present study, as well as those akin to it, provides critical insights into patient management and eventual novel approaches to treatment. Modern immunosuppressive therapy is aimed at damping down the immune system with drugs including glucocorticoids and alkylating agents or at targeting B cells (rituximab). Perhaps future directions should target understanding the factors that open or close conformational antigens or activate or silence genes that transcribe them. Are the real culprits environmental factors including microbes or toxins that alter antigens and the antibody response to them? In autoantibody diseases, we must consider not only the autoantibody but also the autoantigen to which they are binding. DISCLOSURES None." @default.
• W2044394945 created "2016-06-24" @default.
• W2044394945 creator A5053340920 @default.
• W2044394945 creator A5086851939 @default.
• W2044394945 date "2011-10-01" @default.
• W2044394945 modified "2023-09-25" @default.
• W2044394945 title "Autoantibodies" @default.
• W2044394945 cites W1968598953 @default.
• W2044394945 cites W1981778251 @default.
• W2044394945 cites W2008943339 @default.
• W2044394945 cites W2017840451 @default.
• W2044394945 cites W2018025692 @default.
• W2044394945 cites W2019274057 @default.
• W2044394945 cites W2043436124 @default.
• W2044394945 cites W2078610240 @default.
• W2044394945 cites W2096784481 @default.
• W2044394945 cites W2097433467 @default.
• W2044394945 cites W2099244772 @default.
• W2044394945 cites W2101375867 @default.
• W2044394945 cites W2107254198 @default.
• W2044394945 cites W2116367050 @default.
• W2044394945 cites W2127923616 @default.
• W2044394945 cites W2132609447 @default.
• W2044394945 cites W2154713409 @default.
• W2044394945 cites W4233885503 @default.
• W2044394945 doi "https://doi.org/10.1681/asn.2011080836" @default.
• W2044394945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21903994" @default.
• W2044394945 hasPublicationYear "2011" @default.
• W2044394945 type Work @default.
• W2044394945 sameAs 2044394945 @default.
• W2044394945 citedByCount "1" @default.
• W2044394945 countsByYear W20443949452017 @default.
• W2044394945 crossrefType "journal-article" @default.
• W2044394945 hasAuthorship W2044394945A5053340920 @default.
• W2044394945 hasAuthorship W2044394945A5086851939 @default.
• W2044394945 hasBestOaLocation W20443949451 @default.
• W2044394945 hasConcept C126322002 @default.
• W2044394945 hasConcept C142724271 @default.
• W2044394945 hasConcept C159654299 @default.
• W2044394945 hasConcept C163764329 @default.
• W2044394945 hasConcept C203014093 @default.
• W2044394945 hasConcept C2775998817 @default.
• W2044394945 hasConcept C2776015282 @default.
• W2044394945 hasConcept C2776115139 @default.
• W2044394945 hasConcept C2777234017 @default.
• W2044394945 hasConcept C2779134260 @default.
• W2044394945 hasConcept C2780091579 @default.
• W2044394945 hasConcept C2780130043 @default.
• W2044394945 hasConcept C2780368995 @default.
• W2044394945 hasConcept C45189115 @default.
• W2044394945 hasConcept C71924100 @default.
• W2044394945 hasConceptScore W2044394945C126322002 @default.
• W2044394945 hasConceptScore W2044394945C142724271 @default.
• W2044394945 hasConceptScore W2044394945C159654299 @default.
• W2044394945 hasConceptScore W2044394945C163764329 @default.
• W2044394945 hasConceptScore W2044394945C203014093 @default.
• W2044394945 hasConceptScore W2044394945C2775998817 @default.
• W2044394945 hasConceptScore W2044394945C2776015282 @default.
• W2044394945 hasConceptScore W2044394945C2776115139 @default.
• W2044394945 hasConceptScore W2044394945C2777234017 @default.
• W2044394945 hasConceptScore W2044394945C2779134260 @default.
• W2044394945 hasConceptScore W2044394945C2780091579 @default.
• W2044394945 hasConceptScore W2044394945C2780130043 @default.
• W2044394945 hasConceptScore W2044394945C2780368995 @default.
• W2044394945 hasConceptScore W2044394945C45189115 @default.
• W2044394945 hasConceptScore W2044394945C71924100 @default.
• W2044394945 hasIssue "10" @default.
• W2044394945 hasLocation W20443949451 @default.
• W2044394945 hasLocation W20443949452 @default.
• W2044394945 hasOpenAccess W2044394945 @default.
• W2044394945 hasPrimaryLocation W20443949451 @default.
• W2044394945 hasRelatedWork W193921588 @default.
• W2044394945 hasRelatedWork W1981413404 @default.
• W2044394945 hasRelatedWork W1989688128 @default.
• W2044394945 hasRelatedWork W2023277595 @default.
• W2044394945 hasRelatedWork W2032582914 @default.
• W2044394945 hasRelatedWork W2059139640 @default.
• W2044394945 hasRelatedWork W2065351142 @default.
• W2044394945 hasRelatedWork W2079633286 @default.
• W2044394945 hasRelatedWork W2137784344 @default.
• W2044394945 hasRelatedWork W2410385971 @default.
• W2044394945 hasVolume "22" @default.
• W2044394945 isParatext "false" @default.
• W2044394945 isRetracted "false" @default.
• W2044394945 magId "2044394945" @default.
• W2044394945 workType "article" @default.